ZSCAN23: Potential Drug Target and Biomarker for Various Diseases

Target Name: ZSCAN23

NCBI ID: G222696

ZSCAN23: Potential Drug Target and Biomarker for Various Diseases

ZSCAN23 (ZNF390) is a protein that is expressed in various tissues of the body, including the brain, and is known for its role in the development and progression of various diseases, including cancer. ZSCAN23 has also been identified as a potential drug target and biomarker for several diseases, making it an important research topic in the field of biotechnology and medical science.

The ZSCAN23 gene is located on chromosome 6p21.2 and encodes a protein that is composed of 238 amino acid residues. ZSCAN23 is a member of the superfamily of RNA-binding proteins, known as scanlands, and is characterized by a N-terminal transmembrane domain and a C-terminal extracellular domain that is involved in protein-protein interactions.

ZSCAN23 is expressed in a variety of tissues and organs, including the brain, heart, lungs, liver, and kidneys. It is also expressed in various cell types, including neurons, astrocytes, and pericytes, and is involved in the development and maintenance of these cell types.

One of the most significant functions of ZSCAN23 is its role in the development and progression of cancer. Cancer is a complex disease that is characterized by the uncontrolled growth and proliferation of cells that can eventually form tumors. ZSCAN23 has been shown to be involved in the regulation of cell growth and proliferation, as well as the development of cancer-initiating events.

For example, studies have shown that ZSCAN23 plays a role in the regulation of the angiogenic factors, which are molecules that promote the formation of new blood vessels that can supply oxygen and nutrients to tumors. ZSCAN23 has been shown to be involved in the inhibition of angiogenic factors, which may have implications for the development of cancer.

In addition to its role in cancer development, ZSCAN23 has also been shown to be involved in the regulation of cellular processes that are important for normal tissue function. For example, ZSCAN23 has been shown to be involved in the regulation of cell adhesion, which is the process by which cells stick together to form tissues and organs.

ZSCAN23 has also been shown to be involved in the regulation of cell signaling pathways, which are the processes by which cells communicate with one another to regulate various cellular processes. For example, ZSCAN23 has been shown to be involved in the regulation of theNotch signaling pathway, which is a process that is important for the development and maintenance of tissues and organs.

Due to its involvement in a variety of cellular processes, ZSCAN23 has been identified as a potential drug target for several diseases. For example, ZSCAN23 has been shown to be involved in the development of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, and has been identified as a potential therapeutic target for these conditions.

In addition to its potential as a drug target, ZSCAN23 has also been identified as a potential biomarker for several diseases. For example, ZSCAN23 has been shown to be involved in the regulation of cellular processes that are important for the development and progression of cancer, and has been identified as a potential biomarker for cancer.

In addition to its potential as a drug target and biomarker, ZSCAN23 is also of interest to researchers because of its unique structure and function. ZSCAN23 is characterized by a N-terminal transmembrane domain and a C-terminal extracellular domain that is involved in protein-protein interactions. These features make ZSCAN23 a unique protein that is likely to be involved in a variety of cellular processes.

In conclusion, ZSCAN23 is a protein that is of interest to researchers due to its unique structure and function. ZSCAN23 is involved in the regulation of cellular processes that are important for

Protein Name: Zinc Finger And SCAN Domain Containing 23

Functions: May be involved in transcriptional regulation

More Common Targets